Expert Opinion On Therapeutic Targets

Journal Title：Expert Opinion On Therapeutic Targets

The journal evaluates molecules, signalling pathways, receptors and other therapeutic targets and their potential as candidates for drug development. Articles in this journal focus on the molecular level and early preclinical studies. Articles should not include clinical information including specific drugs and clinical trials.

The Editors welcome:

Reviews covering novel disease targets at the molecular level and information on early preclinical studies and their implications for future drug development.

Articles should not include clinical information including specific drugs and clinical trials.

Original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugs.

The audience consists of scientists, managers and decision makers in the pharmaceutical industry, academic researchers working in the field of molecular medicine and others closely involved in R&D.

本期刊评估分子、信号通路、受体和其他治疗靶点及其作为药物开发候选物的潜力。本期刊上的文章侧重于分子水平和早期临床前研究。文章不应包括临床信息，包括特定药物和临床试验。

编辑欢迎：

涵盖分子水平的新疾病靶点的评论以及有关早期临床前研究及其对未来药物开发的影响的信息。

文章不应包括临床信息，包括特定药物和临床试验。

原创研究论文，报告靶点选择和验证研究的结果以及研究和上市药物的基本作用机制研究。

读者包括制药行业的科学家、管理人员和决策者、分子医学领域的学术研究人员以及其他密切参与研发的人员。

Expert Opinion On Therapeutic Targets创刊于2001年，由Taylor and Francis Ltd.出版商出版，收稿方向涵盖医学 - 药学全领域，此刊是该细分领域中属于非常不错的SCI期刊，在行业细分领域中学术影响力较大，专业度认可很高，所以对原创文章要求创新性较高，如果您的文章质量很高，可以尝试。平均审稿速度 偏慢,4-8周 ，影响因子指数4.6，该期刊近期没有被列入国际期刊预警名单，广大学者值得一试。